Damora Therapeutics (DMRA) granted equity awards to five newly hired, non-executive employees on October 1, 2026, as inducements to accept employment.The awards comprise options to purchase 144,400 ordinary shares at an exercise price of $21.28 per share, with a 10-year term. Options vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). The awards are subject to the 2022 Damora Therapeutics Inducement Plan and an option award agreement.

Click to view the official SEC document.

YouTube video by JHS Pedals

Guggenheim named Damora a Best Idea, citing the potential for earlier, longer mCALR treatment to expand the myelofibrosis and essential thrombocythemia markets.

Damora Therapeutics (DMRA) granted equity inducement awards to three newly hired non-executive employees on September 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the company’s independent Compensation Committee as material inducements to the employees’ acceptance of employment.The inducement grants consist of options to purchase an aggregate of 135,400 ordinary shares, each with a 10-year term and an exercise price of $28.18 per share. All options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in equal monthly installments over the following 36 months. The options are granted pursuant to the company’s 2022 Inducement Plan and individual option award agreements.

Click to view the official SEC document.

Click to view the official SEC document.

YouTube video by Navjaxx

Damora Therapeutics (NASDAQ: DMRA) reported second quarter 2026 results highlighted by initiation of the global Phase 1/1b CLARITY-101 trial of lead candidate DMR-001 in mutant calreticulin (mutCALR)-driven essential thrombocythemia and myelofibrosis, following health authority approvals.The company also presented DMR-001 preclinical data at EHA 2026 showing up to 30-fold higher binding affinity, 26-fold greater inhibition of cellular proliferation in Type 2 mutCALR, and a five-fold longer half-life versus a reference antibody, supporting predicted once-monthly subcutaneous dosing. Biotech executive Dr. Andrew Cheng joined the board.Cash and cash equivalents were $540.5 million as of June 30, 2026, which Damora Therapeutics expects to fund operations into the second half of 2029. Second quarter R&D expenses were $25.5 million and G&A $9.5 million, leading to a net loss of $31.2 million, compared with $3.4 million a year earlier. Upcoming milestones include first regulatory submissions for DMR-002 in the second half of 2026 and DMR-003 in 2027, and two clinical proof-of-concept datasets for DMR-001 beginning mid-2027.

Click to view the official SEC document.

-- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer

Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to six newly hired non-executive employees on August 1, 2026. The independent Compensation Committee approved these grants as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).The awards comprise stock options to purchase an aggregate of 451,000 ordinary shares, with a 10-year term and an exercise price of $28.99 per share. Each option vests 25% on the first anniversary of the employee’s start date and then in equal monthly installments over the following 36 months. The options are granted under the 2022 Damora Therapeutics Inducement Plan and are subject to the plan and related option award agreements.

YouTube video by Christelle

An analysis of AH Capital Management's Q1 2026 13F filing. Key changes include an increased NAVN position, a new DMRA holding, and reduced OMDA and FIG stakes.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.